- Home
- ALAR vs ALLK Comparison
ALAR vs ALLK Comparison
Compare ALAR & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALAR
- ALLK
- Stock Information
- Founded
- ALAR 2013
- ALLK 2012
- Country
- ALAR Israel
- ALLK United States
- Employees
- ALAR N/A
- ALLK N/A
- Industry
- ALAR Computer Software: Prepackaged Software
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- ALAR Technology
- ALLK Health Care
- Exchange
- ALAR Nasdaq
- ALLK Nasdaq
- Market Cap
- ALAR 94.0M
- ALLK 101.0M
- IPO Year
- ALAR 2018
- ALLK 2018
- Fundamental
- Price
- ALAR $15.20
- ALLK $0.88
- Analyst Decision
- ALAR Strong Buy
- ALLK Hold
- Analyst Count
- ALAR 2
- ALLK 5
- Target Price
- ALAR $25.50
- ALLK $1.67
- AVG Volume (30 Days)
- ALAR 267.2K
- ALLK 652.1K
- Earning Date
- ALAR 11-25-2024
- ALLK 11-06-2024
- Dividend Yield
- ALAR N/A
- ALLK N/A
- EPS Growth
- ALAR N/A
- ALLK N/A
- EPS
- ALAR 0.07
- ALLK N/A
- Revenue
- ALAR $31,117,000.00
- ALLK N/A
- Revenue This Year
- ALAR $22.15
- ALLK N/A
- Revenue Next Year
- ALAR $11.59
- ALLK N/A
- P/E Ratio
- ALAR $26.07
- ALLK N/A
- Revenue Growth
- ALAR 52.26
- ALLK N/A
- 52 Week Low
- ALAR $4.20
- ALLK $0.54
- 52 Week High
- ALAR $46.69
- ALLK $3.41
- Technical
- Relative Strength Index (RSI)
- ALAR 55.47
- ALLK 38.32
- Support Level
- ALAR $12.05
- ALLK $1.29
- Resistance Level
- ALAR $16.07
- ALLK $1.56
- Average True Range (ATR)
- ALAR 1.37
- ALLK 0.13
- MACD
- ALAR -0.06
- ALLK -0.07
- Stochastic Oscillator
- ALAR 78.36
- ALLK 10.53
About ALAR Alarum Technologies Ltd.
Alarum Technologies Ltd is a company engaged in the information security business. The company has two Internet access segments which include Enterprise Internet Access and Consumer Internet Access. Its Enterprise Internet Access offers web data collection and a private Internet browsing platform and Consumer Internet Access provides solutions for secure and private Internet browsing. Geographically, the company has a presence in the UK Virgin Islands, Israel, Europe, APAC, MEA, Hong Kong, the USA, and others, and generates a majority of its revenue from the APAC followed by the United States.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.